A new study has identified an increased risk of lung cancer and heart disease in night shift workers, adding to the growing knowledge of health risks associated with those jobs.
Working rotating night shifts may pose a threat to your health, a new study suggests.
The study defined rotating shift work as at least 3 nights spent working each month, in addition to days and evenings worked in the month.In the new study, researchers led by Eva Schernhammer, MD, DrPH, of Harvard Medical School tracked 22 years of data from about 75,000 nurses across the United States. While the study couldn't prove cause-and-effect, it found that people who worked rotating night shifts for more than 5 years had an 11% increased risk of death from all causes. The risk of death from heart disease was 19% higher among those who worked such shifts for 6 to 14 years, and 23% higher for those who worked such shifts for 15 or more years, Dr Schernhammer's group found. Nurses who worked rotating night shifts for 15 or more years also had a 25% higher risk of death from lung cancer, according to the study.
American Journal of Preventive Medicine
The findings are to be published in the March issue of the .
Read the article on MedlinePlus
Night shift workers have previously been shown to be at a greater risk for developing diabetes.
Oncology Onward: A Conversation With Penn Medicine's Dr Justin Bekelman
December 19th 2023Justin Bekelman, MD, director of the Penn Center for Cancer Care Innovation, sat with our hosts Emeline Aviki, MD, MBA, and Stephen Schleicher, MD, MBA, for our final episode of 2023 to discuss the importance of collaboration between academic medicine and community oncology and testing innovative cancer care delivery in these settings.
Listen
FDA Approves Tislelizumab for Advanced or Metastatic ESCC After Chemotherapy
March 15th 2024The FDA has approved tislelizumab-jsgr (Tevimbra) for single-agent use in adult patients with unresectable or metastatic esophageal squamous cell carcinoma following prior systemic chemotherapy that did not include a PD-1/PD-L1 inhibitor.
Read More